AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against MacroGenics, Inc. (MGNX) and November 12 Deadline

November 5, 2019

NEW YORK--(BUSINESS WIRE)--Nov 5, 2019--

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is reminding investors that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX), and certain other defendants, related to alleged violations of federal securities laws. If you purchased MacroGenics common stock between February 6, 2019 and June 3, 2019, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for more information. The lead plaintiff deadline is November 12, 2019.

MacroGenics is a clinical stage biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of cancer.

The lawsuit alleges that, throughout the Class Period, defendants misled investors regarding the results of the Company’s SOPHIA clinical trial evaluating product candidate margetuximab. SOPHIA is a randomized, open-label Phase III clinical trial evaluating margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer.

On May 15, 2019, MacroGenics issued a press release entitled “MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer.” The release touted positive results in progression-free survival (“PFS”) rates.

Then, on June 4, 2019, the Company disclosed additional data for the SOPHIA trial including that it had conducted both the PFS and first interim overall survival (“OS”) analyses in October 2018, and that the OS analyses did not produce a statistically significant result.

As a result of this news, the price of MacroGenics stock fell nearly 17%, or $3.13 per share, to close at $15.58 on June 4, 2019. On June 5, 2019, the price of MacroGenics stock declined another 6%.

What You Can Do

If you purchased MacroGenics stock between February 6, 2019 and June 3, 2019, inclusive, or if you have questions about this notice or your legal rights, you are encouraged to contact attorney Rhiana Swartz at (844) 818-6980 or rswartz@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

View source version on businesswire.com:https://www.businesswire.com/news/home/20191105005362/en/

CONTACT: Rhiana Swartz

Scott+Scott Attorneys at Law LLP

230 Park Avenue, 17 Floor, New York, NY 10169-1820

(844) 818-6980

rswartz@scott-scott.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES

SOURCE: Scott+Scott Attorneys at Law LLP

Copyright Business Wire 2019.

PUB: 11/05/2019 10:00 AM/DISC: 11/05/2019 10:00 AM

http://www.businesswire.com/news/home/20191105005362/en